Source-agnostic · Triangulated · Evidence-graded
Type any molecule.
Vireka assembles the dossier live.
The signal beneath the noise — the hidden truth in public data.
A competitive-intelligence desk that pulls from every free, public source — clinical trials, FDA, literature, quarterly filings, global news, and social — then triangulates each finding, grading it high / medium / low confidence by how many independent, reliable sources confirm it.
Try:
The dossier
Molecule, company & TA
Identity, brands, ATC class, therapeutic area
Development pipeline
Trials by phase, sponsors, indications
Lifecycle & convenience
Formulations, expansions, patient burden
Medical benefit
Evidence base & key publications
Launch & peri-launch
Recent approvals, rollout signals
Payer access (HTA)
NICE/ICER/HAS verdicts across countries
Biosimilar / generic threat
Exclusivity, patents, LOE exposure
Portfolio context
The sponsor's other marketed assets
Competitive landscape
Sponsors & assets in the same space
Media & social sentiment
News tone + investor social, by lens
News, every perspective
Regulatory · commercial · legal · deal · pricing
Quarterly & investor filings
10-Q / 10-K / 8-K that name the asset
Every free public source
TrialsClinicalTrials.govPipeline, phases, sponsors, indications
RegulatoryopenFDAApprovals, labels, post-market safety
LiteraturePubMedClinical evidence & benefit signals
FinancialSEC EDGAR10-Q / 10-K / 8-K quarterly disclosures
AccessHTA bodiesNICE, ICER, SMC, HAS, CADTH, PBAC, G-BA reimbursement
ExclusivityFDA Orange BookPatents & exclusivity → loss-of-exclusivity dates
NewsGDELT + Google NewsGlobal coverage, every perspective
SocialStockTwitsInvestor social sentiment (Bullish/Bearish)
ReferenceRxNorm / RxNavNames, brands, ATC class normalisation
Data pulls require no API keys. AI synthesis, the ask-us service, and saved dossiers light up when their keys are configured — see the source-health strip on any dossier.